Related Experiment Video

Updated: May 27, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy

Liying Yang1, Tomohisa Horibe, Masayuki Kohno

  • 1Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, Japan.

Molecular Cancer Therapeutics
|November 16, 2011
PubMed

Insights

A novel hybrid peptide selectively targets and kills Interleukin-4 receptor α (IL-4Rα)-positive cancer cells. This peptide shows potent anticancer activity in vitro and significantly inhibits tumor growth in vivo, offering a promising new cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Interleukin-4 receptor α (IL-4Rα) is overexpressed on many human solid tumors.
  • Targeting IL-4Rα presents a potential strategy for selective cancer therapy.

Purpose of the Study:

  • To design and evaluate a novel hybrid peptide, IL-4Rα-lytic peptide, for targeted cancer treatment.
  • To assess the in vitro and in vivo anticancer efficacy of the IL-4Rα-lytic peptide.

Main Methods:

  • Quantitative real-time PCR to determine IL-4Rα expression levels.
  • In vitro cytotoxicity assays on cancer cell lines.
  • In vivo studies using a human pancreatic cancer xenograft mouse model.

Main Results:

  • IL-4Rα-lytic peptide demonstrated significant cytotoxic activity against IL-4Rα-expressing cancer cells.
  • A strong correlation (r = 0.80) was observed between IL-4Rα expression levels and peptide efficacy.
  • Intratumoral and intravenous administration of the peptide significantly inhibited tumor growth in mice.

Conclusions:

  • The designed IL-4Rα-lytic peptide exhibits potent and selective anticancer potential.
  • This hybrid peptide is a promising candidate for treating IL-4Rα-positive solid tumors.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...